Global Angiosarcoma Treatment Market, By Treatment (Surgery, Radiotherapy, Chemotherapy, Targeted Therapy, Immunotherapy), Location of Instigation (Hemangiosarcoma, Lymphangiosarcoma), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2029
Market Analysis and Insights Global Angiosarcoma Treatment Market
The angiosarcoma treatment market is expected to witness market growth at a rate of 5.10% in the forecast period of 2022 to 2029. Data Bridge Market Research report on angiosarcoma treatment market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market’s growth. The rise in the prevalence of chronic diseases globally is escalating the growth of angiosarcoma treatment market.
Angiosarcoma (AS) refers to a rare and highly aggressive malignant tumor that generally originates from lymphatic or vascular endothelial-cell. This type of tumor makes up less than 2% of all soft tissue sarcomas in humans, and tends to affect adult and elderly patients. Angiosarcoma can occur in any location of body, as a clinically and genetically heterogeneous subgroup of sarcomas.
The increase in the prevalence of cancer across the globe acts as one of the major factors driving the growth of angiosarcoma treatment market. The rise in demand for targeted medicines and immunotherapy as treatment for the disease and increase in the in the adoption of advanced cancer therapeutic options accelerate the market growth. The introduction of newer drug classes, such as monoclonal antibodies and histone deacetylase (HDAC) inhibitors and development of bioinformatic tools enhancing drug development process further influence the market. Additionally, rise in geriatric population, growth in awareness, development in technology and surge in healthcare expenditure positively affect the angiosarcoma treatment market. Furthermore, increase in clinical trials extend profitable opportunities to the market players in the forecast period of 2022 to 2029.
On the other hand, high cost associated with the treatment and availability of limited funds to initiate clinical trials are expected to obstruct the market growth. Complexity of cancer limiting the immune response is projected to challenge the angiosarcoma treatment market in the forecast period of 2022-2029.
This angiosarcoma treatment market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info angiosarcoma treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Angiosarcoma Treatment Market Scope and Market Size
The angiosarcoma treatment market is segmented on the basis of treatment, location of instigation, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of treatment, the angiosarcoma treatment market is segmented into surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy. Chemotherapy is further segmented into anthracyclines and taxanes. Targeted Therapy is further segmented into vascular endothelial growth factor (VAGR) and adrenergic receptors.
- On the basis of location of instigation, the angiosarcoma treatment market is segmented into hemangiosarcoma and lymphangiosarcoma.
- On the basis of end-users, the angiosarcoma treatment market is segmented into hospitals, homecare, specialty clinics and others.
- On the basis of distribution channel, the angiosarcoma treatment market is segmented into hospital pharmacy, retail pharmacy and online pharmacy.
Angiosarcoma Treatment Market Country Level Analysis
The angiosarcoma treatment market is analyzed and market size information is provided by country, treatment, location of instigation, end user and distribution channel as referenced above.
The countries covered in the global angiosarcoma treatment market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America dominates the angiosarcoma treatment market due to the presence of developed healthcare infrastructure within the region. Asia-Pacific is expected to witness high growth during the forecast period of 2021 to 2028 because of the large population in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The angiosarcoma treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Angiosarcoma Treatment Market Share Analysis
The angiosarcoma treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related angiosarcoma treatment market.
Some of the major players operating in the angiosarcoma treatment market report are F. Hoffmann La Roche Ltd, Novartis AG, Bayer AG, GlaxoSmithKline plc, Sanofi, Amgen Inc, Merck & Co., Inc, AbbiVie Inc, Eli Lilly and Company, Bausch Health, Johnson & Johnson Services Inc, Bristol Myers Squibb and Company, AstraZeneca, Pfizer Inc, Teva Pharmaceutical Industries Ltd, and Hikma Pharmaceuticals plc, among others.
SKU-